Device Trial Radar · NCT05090748
Study for the Assessment of the Quality of Echocardiographic Clips.
Last checked: Nov 19, 2026Latest source record: Dec 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
May 15, 2022
Primary completion
Aug 5, 2022
Study completion Aug 31, 2022
Sponsor
- Lead sponsor
- UltraSightNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 25, 2021
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study main objective is to evaluate the safety and efficacy of the UltraSight AI Guidance software. The investigational product is a software that guides the user to capture a high quality ultrasound image. The study will include healthcare professionals, not specialized in echocardiography, who will perform echocardiography by using UltraSight AI Guidance software, on subjects in the medical centers cardiac units.
Conditions
- Cardiac Disease
Interventions
Echocardiographic.Device
Echocardiographic test.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the echo examination sufficiency.Time frame: 1 year.
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
University of Chicago Medicine
Chicago, Illinois
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin
Sheba MC
Ramat Gan, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.